|
-
Being tested in AIDS studies that involve suppressing T
cells to stop viral growth. This is a radically different approach to
treating HIV infection. Peldesine (BCX-34) is expected to reduce the
speed with which the virus develops resistance. The drug's action is
highly reversible. T-cell counts return to pretreatment levels within
two weeks after the drug is discontinued. [AIDS Alert 1997 Jul;12(7);
BUSINESS WIRE / HealthWire April 30 1997]
-
Marker for incorporation into cellular DNA to measure
lymphocyte kinetics[NIAID 97-I-0189]
-
(+)-Calanolide A is a novel non-nucleoside reverse
transcriptase inhibitor with potent in vitro activity against HIV-1 and
unique pharmacokinetic properties. [5th Conf Retrovir Oppor Infect 1998
Feb 1-5]
-
The safety and efficacy of SU5416 in patients with
Kaposi's sarcoma, who have failed currently available therapy, is being
investigated in phase I/II clinical trials. [SUGEN Press Release, May
15, 1998]
-
T-20 blocks cell fusion and viral entry at
concentrations of less than 2 ng/ml in vitro. Fusion of a viral envelope
with a target cell membrane is required for the initiation of infection
and, therefore, virus replication. [Nat Med. 1998 Nov;4(11); Trimeris
Information]
-
Being tested in Phase II studies against HIV
infection[AmFAR Tx Dir 1998;9(2)]
-
Being tested for treatment of aspergillosis. [AmFAR Tx
Dir December, 1997]
-
Being tested as topical treatment against Kaposi's
sarcoma[PR Newswire 05 Jan 96]
-
Under investigation for intravitreal use against ocular
CMV infection, and for systemic use against CMV infections in AIDS
patients. [PR NewsWire April 7, 1997; PR NewsWire April 7, 1997]
-
Anti-HIV activity. Currently in clinical phase I
trials[Mol Pharmacol 1998 Feb; 53(2)]
-
To prevent HIV infection. The end points of the ongoing
clinical studies are infection, as defined by seroconversion to standard
diagnostic tests, and viral load, as defined by commercial polymerase
chain reaction (PCR) tests. [Business Wire, February 9, 1999]
-
Vaccine against HIV infection. The FDA has granted
permission for Phase III trials of the vaccine. Such are being initiated
in the US with the AIDSVAX B/B vaccine, and in Thailand with AIDSVAX
B/E, a slightly different version of the vaccine. [Science 1998 Jan
30:279(5351); AP, June 3, 1998]
-
Human IL-6 is characterized as a glycoprotein
consisting of 212 amino acids with numerous post-translational
modifications including phosphorylations as well as N- and O-linked
glycosylations. [Frontiers Bioscience 1, Dec 1996; In Vivo Veritas Jan
1996]
-
Non-Hodgkin's Lymphoma. [AmFAR Tx Dir 1997;8(3)]
-
In clinical trial against fluconazole-resistant
candidiasis. [AmFAR Tx Dir 1997;8(3)]
-
Lamivudine/zidovudine reduces HIV RNA and raises CD4
counts relative to control treatments. FDA approved the combination drug
on 9/29/97 for the treatment of HIV infection. [AIDS. 1997 Mar
15;11(4):477-83]
-
Prophylactic against Mycobacterium Avium Complex in
AIDS patients with CD4 count less than or equal to 75/cubic mm. [USP DI
1997]
-
In combination with other antifungal agents, being test
against Cryptococcus neoformans infections. [Antimicrob Agents
Chemother. 1997 Feb;41(2)]
-
Therapy for Kaposi's Sarcoma. [Int Conf AIDS 1996 Jul
7-12;11(1):18]
-
Anti-HIV vaccine[Vaccine 1995, Dec; 13(17)]
-
Erythromycin is used to treat patients with severe
anemia that is ascribed to HIV infection or to AZT treatment. [Ann
Internal Medicine 1992]
-
Under investigation for treatment of microsporidiosis.
[AmFAR Tx Dir 1997;8(3)]
-
Study of immune activaton and HIV expression in early
HIV disease. [ACTG 334]
-
Under investigation as a caloric supplementation to
improve growth in HIV-infected infants. [NIAID ACTG 247]
-
Under investigation for the treatment of primary HIV
infections. [FDA 269A]
-
Being tested as oral treatment of CMV retinitis[AmFAR
Tx Dir December, 1997]
-
Inhibitor of HIV-1 reverse transcriptase. [AmFAR Tx Dir
1997;8(3)]
-
Treatment of Kaposi's sarcoma[Int Conf AIDS. 1996 Jul
7-12;11(2)]
-
The cytoprotective effect of memantine in cortical cell
cultures may qualify the drug for the treatment of AIDS-related
dementia. [Eur J Pharmacol 1993 Aug 10;240(1)]
-
In testing for treatment of cytomegalovirus
infection[4th Conf Retro and Opportun Infect. 1997 Jan 22-26]
-
Prophylactic to prevent influenza in HIV-infected
persons. [AHFS Drug Information 1997]
-
Treatment of hypogonadism associated with megestrol
acetate administration in HIV+ women. Used in the management of HIV
associated anorexia and weight loss. [AmFAR Tx Dir December, 1997; Annu
Conf Australas Soc HIV Med 1997 Nov 13-16;9]
-
FDA approved 03/14/97 for the treatment of HIV
infection when antiretroviral therapy is warranted in adults and
pediatrics >=2 years old. [PDR 1999]
-
Under investigation for the treatment of primary HIV
infections in asymptomatic HIV-1 infected patients. [NIAID 97
I-032]
-
Under investigation for the treatment of primary HIV
infections. [FDA 258A]
-
Treatment of wasting syndrome. [AmFAR Tx Dir
1996;8(2)]
-
HIV infection. [NIAID 94 I-202]
-
The FDA has approved abacavir (12/18/98) for the
treatment of HIV-1 infection in adults and children. Studies suggest
that abacavir is most effective when used as part of a triple
combination therapy regimen. Abacavir shows the potential of being an
important addition to the arsenal of anti-HIV drugs, especially for
people who have already outlived the usefulness of other drugs of this
class or who need it as part of a fresh combination with protease
inhibitors. [Project Inform Fact Sheet, 1/99; FDA Talk Paper, 1998 Dec
18]
-
HIV infection. [NIAID ACTG 307]
-
Oropharyngeal candidiasis. [NCI 96 C-41]
-
HIV infection. [FDA 257A]
-
Pain related to HIV. [FDA 256A]
-
HIV-related peripheral neuropathy. [NIAID ACTG
291]
-
Prevention of varicella ( chickenpox ) in HIV-infected
patients. [NIAID ACTG 265]
-
HIV infection. [FDA 092]
-
HIV infection. [NCI 95 C-192]
-
Enhancement of immune function in HIV infection.
[Physicians GenRx 1996]
-
FDA Approved 03/14/97 for use alone or in combination
with nucleoside analogues for treatment of HIV infection in pediatrics
>=2 years old. Indicated in combination with nucleoside analogs or as
monotherapy for the treatment of HIV-infection when therapy is
warranted. [Facts and Comparisons 1996; PDR 1999]
-
Prevention of HIV infection. [NIAID VEU 026]
-
AIDS-related cryptosporidiosis. [FDA 253B]
-
Primary HIV infection. [FDA 252A]
-
HIV-associated pneumococcal disease. [NIAID ACTG
292]
-
HIV-associated pneumococcal disease. [NIAID ACTG
292]
-
Cutaneous lesions from Kaposi's sarcoma and
lymphoproliferative disorders. [FDA 247A]
-
HIV-associated dementia. [FDA 250A]
-
HIV-associated dementia. [FDA 250A]
-
Cytomegalovirus (CMV) infections; HIV infection; Herpes
infection. [FDA 248A; AmFAR Tx Dir 1997;8(3)]
-
FDA approved on August 26, 1998 for the local treatment
of cytomegalovirus (CMV) retinitis in patients with AIDS who are
intolerant of or have a contraindication to other treatment(s) for CMV
retinitis or who were insufficiently responsive to previous treatment(s)
for CMV retinitis. [Int Conf AIDS 1994 Aug 7-12;10(2)]
-
Primary HIV infection. FDA approved 3/14/96 for use alone or in
combination with nucleoside analogues for treatment of HIV infection
in adults. [Prog Abst Intersci Conf Antimicrob Agents Chemother 1994
Oct; Merck & Co Package Insert 3/96]
-
Primary HIV infection. [FDA 090]
-
Primary HIV infection. [NCI 94 C-159]
-
Prevention of HIV infection. [NIAID VEU 022]
-
Enhancement of immune response and inhibition of tumor necrosis
factor production in HIV infection. [NIAID 95 I-125]
-
Primary HIV infection. [FDA 089]
-
HIV-associated nephropathy; HIV-associated idiopathic esophageal
ulcer. [Am J Med 1994 Aug;97(2); Am J Gastroenterol 1994 Dec;89(12)]
-
HIV-related cognitive dysfunction. [FDA 242A]
-
AIDS-associated sinusitis. [FDA 243A]
-
Primary HIV infection. [NIAID DATRI 010]
-
Under investigation for the treatment of AIDS-related
non-Hodgkin's lymphoma. [AmFAR Tx Dir 1997;8(3)]
-
Prevention of HIV infection. [NIAID VEU 019]
-
Possible prevention or reversal of sensitivity to SMX in patients
with HIV infection and SMX intolerance. [NIAID 95 I-126]
-
Alleviation or elimination of hypocalcemia and hypomagnesemia
associated with foscarnet infusion. [FDA 020J]
-
Primary HIV infection. [Int Conf AIDS 1994 Aug 7-12;10(2)]
-
Treatment of psoriasis in HIV-positive patients. [FDA 239A]
-
Inhibitor of Kaposi's sarcoma. [AmFAR Tx Dir 1995;7(4)]
-
Primary HIV infection. [NIAID ACTG 282]
-
Primary HIV infection. Drug development discontinued per company.
[FDA 237A; Glaxo Wellcome 4/96]
-
Toxoplasmic encephalitis. [NIAID ACTG 237; AHFS Drug Information
1997]
-
Treatment of anal neoplasia secondary to anogenital human
papillomavirus infection. [NIAID ACTG 216; AmFAR Tx Dir 1997;8(3)]
-
Prevention of HIV infection. [NIAID VEU 018]
-
Zidovudine-induced myopathy resulting from carnitine deficiency. [NINDS
93 N-30]
-
Under investigation in the US as a treatment for HIV and Kaposi's
sarcoma. [FDA 234A; AmFAR Tx Dir 1997;8(3)]
-
Primary HIV infection. [FDA 232A]
-
Antiviral nucleoside analog drug currently in development.
Structurally, FTC is similar to 3TC (Lamivudine), but in vitro, it
appears to be much more potent against HIV than 3TC. Now in phase
II/III clinical trials in HIV-infected patients. [BETA. 1998
Jul;:38; Triangle Pharmaceuticals, Jan. 26, 1999]
-
Treatment of AIDS-related non-Hodgkin's lymphoma. [NCI 93 C-207]
-
Prevention of HIV infection. [NIAID VEU 014]
-
Prevention of HIV infection. [NIAID VEU 017]
-
WF10 is thought to enhance immune function in late stage HIV
infection. It is intravenously administered and targets macrophage
function. Even HAART (highly active antiretroviral therapy) does not
appear effective against the latent HIV surviving in macrophages, a
known reservoir of the virus in AIDS patients. [PR Newswire January
7, 1993; Infection 1998 July/August;26(4):201-206]
-
Under investigation for refractory AIDS-related diarrhea. [AmFAR
Tx Dir 1997;8(3)]
-
Primary HIV infection. [FDA 221A]
-
Treatment of HIV-associated multi-drug resistant pulmonary
tuberculosis. [NIAID ACTG 238]
-
Treatment of multi-drug resistant pulmonary tuberculosis. [NIAID
ACTG 238]
-
Used as second-line therapy in combination with other
antituberculosis drugs for pulmonary tuberculosis. [PDR 1997]
-
As an active placebo to mimic the side effects of study drugs. [NIAID
ACTG 242]
-
Relief or reduction of pain in HIV-associated peripheral
neuropathy. [NIAID ACTG 242]
-
Used as a second-line agent against tuberculosis in the
HIV-infected person. It should be given only with other effective
antituberculosis drugs. [NIAID ACTG 238; Drug Evaluations Annual
1995]
-
Used in the treatment of active pulmonary and extrapulmonary
tuberculosis (including renal disease). When the causative organisms
are susceptible to the drug and when treatment with primary
medications (streptomycin, isoniazid, rifampin and ethambutol) has
proved inadequate. Should be administered with other effective
chemotherapy and not as the sole therapeutic agent. [PDR 1997]
-
Prevention of hypochlorhydria, in order to enhance absorption of
oral ganciclovir. [NIAID ACTG 183]
-
Primary HIV infection. [NIAID ACTG 259]
-
Inhibition of tumor necrosis factor production in HIV infection. [NIAID
ACTG 232]
-
HIV-associated thrombocytopenia. [NCI 93 C-155]
-
FDA approved (8/5/97) for the second-line treatment of
AIDS-related Kaposi's sarcoma. [MeadJohnson/Bristol-Myers Squibb
Package Insert 8/97]
-
Inhibition of tumor necrosis factor production in HIV infection. [AmFAR
Tx Dir 1995;7(4)]
-
Currently being investigated for treatment of cryptosporidiosis. [AmFAR
Tx Dir 1997;8(3); NIAID ACTG 192]
-
Enhancement of immune response in HIV infection. [AmFAR Tx Dir
1995;7(4)]
-
Inhibition of tumor necrosis factor production in HIV infection. [NIAID
93 I-182]
-
Treatment of AIDS related Kaposi's sarcoma. FDA approved 11/17/95
for the treatment of Kaposi's sarcoma in AIDS patients with disease
that has progressed on prior combination chemotherapy or in patients
who are intolerant to such therapy. [PDR 1997; FDA Bulletin]
-
Currently being studied for possible treatment of mycobacterium
infection and wasting syndrome in HIV infection. Successful results
have been reported in treatment of various ulcerations including
recurrent aphthous stomatitis (RAS). [DICP 1990 Nov; Vol 24 No 11;
FDA 133A, FDA 230A; AIDS Therapies 1995 Sep]
-
For use with concurrent leucovorin administration as an
alternative therapy for the treatment of moderate to severe
Pneumocystis carinii pneumonia (PCP) in immunocompromised patients,
including those with AIDS, who are intolerant of, or are refractory
to, trimethoprim/sulfamethoxazole (TMP-SMX), or for whom TMP-SMX is
contraindicated. [PDR 1997]
-
Under investigation in combination with amphotericin B in patients
with cryptococcal meningitis. [AmFAR Tx Dir 1997;8(3)]
-
Used as control in vaccine studies. [NIAID VEU 012A]
-
Prevention of HIV infection. [NIAID VEU 012A]
-
Treatment of localized herpes zoster. [FDA 130A; AmFAR Tx Dir
1995;7(4)]
-
Primary HIV infection: as a vaccine adjuvant for the enhancement
of the immune response. [NIAID VEU 016; AIDS Res Hum Retroviruses
1995 Feb;11(2)]
-
Primary HIV infection: as a vaccine adjuvant for the enhancement
of the immune response. [NIAID VEU 015]
-
Primary HIV infection: as a vaccine adjuvant for the enhancement
of the immune response. Used as an emulsifier system in conjunction
with other adjuvants such as MTP-PE. [NIAID VEU 015; J Infect Dis
1994 Nov;170(5); J Infect Dis 1994 Nov;170(5)]
-
Primary HIV infection: as a vaccine adjuvant for the enhancement
of the immune response. [NIAID VEU 015]
-
Primary HIV infection: as a vaccine adjuvant for the enhancement
of the immune response. [NIAID VEU 015]
-
Primary HIV infection: as a vaccine adjuvant for the enhancement
of the immune response. [NIAID VEU 015]
-
Primary HIV infection: as a vaccine adjuvant for the enhancement
of the immune response. [NIAID VEU 015]
-
Enhancement of immune function in HIV infection. [FDA 126A]
-
Tested for the treatment of Cytomegalovirus retinitis. [AmFAR Tx
Dir 1995;7(4)]
-
Relief or reduction of pain caused by HIV-associated peripheral
neuropathy. [NIAID CPCRA 022]
-
AIDS-related Kaposi's sarcoma. [AmFAR Tx Dir 1997;8(3)]
-
Prophylaxis against HIV infection. [NIAID VEU 011]
-
FDA approved 04/04/97 for use in combination with appropriate
antiretrovirals when therapy is warranted for treatment of HIV
infection. Delavirdine should always be administered with at least
one other antiretroviral agent; it should not be used alone in the
management of HIV infection. In clinical studies to date it has been
used in combination with one or two dideoxynucleoside reverse
transcriptase inhibitors such as zidovudine lamivudine or didanosine,
for initial management. [AHFS Drug Information 1998]
-
Enhancement of CD4 lymphocyte levels in patients being treated for
primary HIV infection. [NIAID ACTG 236]
-
FDA-approved for use in adults in combination with other
antiretrovirals. It was first approved in a hard-gel capsule
formulation (Invirase) that was poorly absorbed when given orally.
Recently, a soft-gel capsule formulation (Fortovase) with increased
bioavailability was approved. [AmFAR Tx Dir 1998;9(2)]
-
Enhancement of immune function in HIV infection. [FDA 122A]
-
HIV infection. [AmFAR Tx Dir 1997;8(3)]
-
Vaginal application of cream to prevent recurrence of
cervical/vaginal dysplasia. [NIAID ACTG 200]
-
Prevention of recurrent HIV-associated sinusitis. [NIAID ACTG 186]
-
Prevention of recurrent HIV-associated sinusitis. [NIAID ACTG 186]
-
Prevention of recurrent HIV-associated sinusitis. [NIAID ACTG 186]
-
Prevention of recurrent HIV-associated sinusitis. [NIAID ACTG 186]
-
HIV infection. [AmFAR Tx Dir 1997;8(3); Int J Cancer 1995
Mar;61(1)]
-
FDA approved 4/8/96 as first-line therapy for advanced
HIV-associated Kaposi's sarcoma. [NeXstar Pharmaceuticals Press
Release 4/30/96]
-
HIV infection. [AmFAR Tx Dir 1993;6(4)]
-
HIV infection. [AmFAR Tx Dir 1997;8(3)]
-
HIV infection. [AmFAR Tx Dir 1997;8(3)]
-
Treatment of herpes simplex virus lesions. [FDA 120A; AmFAR Tx Dir
1997;8(3)]
-
Enhancement of immune function in HIV infection. [AmFAR Tx Dir
1995;7(4)]
-
Under investigation for the treatment of chronic diarrhea in
HIV-infected people. [AmFAR Tx Dir 1997;8(3)]
-
Under investigation for treatment of Kaposi's sarcoma. [AmFAR Tx
Dir 1997;8(3)]
-
Under investigation for the oral treatment of Kaposi's sarcoma. [AmFAR
Tx Dir 1997;8(3); J Clin Oncol 1995 May;13(5)]
-
Enhancement of immune function in HIV infection. [Blood 1993 Apr
15;81(8)]
-
Treatment of herpes simplex virus and cytomegalovirus (CMV)
retinitis in patients with AIDS. FDA approved 6/27/96 for CMV
retinitis. [USP DI 1999; Gilead Sciences Package Insert July 1996;
AHFS Drug Information 1999]
-
Primary HIV infection. [AmFAR Tx Dir 1995;7(4)]
-
Being investigated for treatment of tuberculosis. Treatment of MAI
(Mycobacterium avium-intracellulare) bacteremia in HIV-infected
individuals. [Tuber Lung Dis 1992 Dec;73(6); NIAID 92 I-165; AmFAR
Tx Dir 1993;6(3)]
-
Used as non-HIV viral vaccine control. [NIAID ACTG 205]
-
Treatment of HIV-infected patients with CMV viruria. [NIAID 92
I-124]
-
Being investigated as prophylaxis or treatment for Pneumocystis
carinii pneumonia in HIV-infected patients. [AmFAR Tx Dir 1993;6(4);
NIAID ACTG 173]
-
Under investigation for the treatment of AIDS dementia complex. [AmFAR
Tx Dir 1995;7(4)]
-
FDA approved 12/23/92 for appetite stimulation and the prevention
of weight loss in HIV-infected patients. [AmFAR Tx Dir 1995;7(4);
USP DI 1997]
-
Being investigated for the treatment of cryptosporidiosis.
Paromomycin and letrazuril should be considered in the treatment of
AIDS-related sclerosing cholangitis. [AmFAR Tx Dir 1997;8(3); AIDS.
1993 Nov;7(11)]
-
Active against HSV-1 and varicella-zoster virus (VZV). [AmFAR Tx
Dir 1997;8(3)]
-
Treatment of Hodgkin's disease in HIV-infected patients. [AmFAR Tx
Dir 1995;7(4); NIAID ACTG 149]
-
Treatment of Hodgkin's disease in HIV-infected patients; Kaposi's
sarcoma. [Int Conf AIDS 1993 Jun 6-11;9(1)]
-
Diagnostic aid to detect Mycobacterium tuberculosis infections. [AHFS
Drug Information 1997]
-
Studied as a treatment for HIV-related wasting and being
investigated for its role in the human immune system. [AmFAR Tx Dir
1995;7(4)]
-
Mediates effects of human growth hormone, used to treat
HIV-associated wasting. [AmFAR Tx Dir 1995;7(4); J Clin Endocrinol
Metab 1994 Feb;78(2)]
-
Possible inhibition of the metabolic inactivation of zidovudine
(AZT), resulting in a longer duration of AZT effects in the body. [Int
Conf AIDS 1992 Jul 19-24;8(3)]
-
Primary HIV infection; tuberculosis. [AmFAR Tx Dir 1995;7(4);
NIAID DATRI 008; NIAID ACTG 222]
-
Bactericidal action against penicillin G-susceptible
microorganisms. [PDR 1997]
-
Antiviral treatment. [Facts and Comparisons 1995; Antimicrob
Agents Chemother 1994 Feb;38(2)]
-
Lamivudine has been approved (1995) by the FDA for use in
combination with AZT in HIV+ patients under the accelerated approval
regulations. Lamivudine has demonstrated antiviral activity in
combination with many other antiretrovirals including nucleoside
analogs such as stavudine and protease inhibitors. [AmFAR Tx Dir
1998;9(2)]
-
Indicated to prevent or treat peripheral neuritis caused by drugs
that act as pyridoxine antagonist (eg. isoniazid) and/or increase
its excretion in the urine. [Drug Evaluations Annual 1995]
-
An oral antituberculosis drug used in combination regimens.
Prophylaxis against Mycobacterium tuberculosis (MTb) in persons
dually infected with HIV and MTb. (Used in conjuction with rifampin
to help overcome drug resistance.)[NIAID ACTG 177]
-
An antibiotic which, in combination regimens, is standard for the
treatment and prophylaxis of tuberculosis in the HIV infected
patient. Administered concurrently with pyridoxine (vitamin B6) to
prevent the peripheral neuropathy as well as nearly all other
nervous system disorders attributable to isoniazid (INH). [AHFS Drug
Information 1997; NIAID ACTG 177]
-
Subcutaneous treatment of HIV associated cytopenia. [AmFAR Tx Dir
1995;7(4)]
-
Applied over trifluridine in a clinical study of the effectiveness
of trifluridine for HZV infection in AIDS patients (ACTG 172). [NIAID
ACTG 172]
-
Used experimentally for the treatment of acyclovir-resistant and
foscarnet-resistant HZV infection. Herpes simplex, mucocutaneous (at
nasal, oral, vaginal, and anal openings). [AmFAR Tx Dir 1995;7(4);
NIAID ACTG 172]
-
Oral valacyclovir is used for the treatment of acute, localized
herpes zoster (shingles) and for the treatment of initial episodes
of genital herpes infections in immunocompetent adults. Efficacy for
the treatment of disseminated herpes zoster in immunocompromised
adults has not been established. [AHFS Drug Information 1999]
-
Primary HIV infection. [AmFAR Tx Dir 1995;7(4)]
-
Under investigation for the treatment of HIV infection and
Kaposi's sarcoma. [AmFAR Tx Dir 1997;8(3)]
-
HIV infection. FDA approved 6/24/96 for use in combination with
approved nucleoside analogues for treatment of HIV-infected adults
who have experienced clinical and/or immunologic deterioration. [AmFAR
Tx Dir 1997;8(3); Boehringer Ingelheim Pharmaceuticals]
-
Under investigation for the treatment of cryptosporidiosis and
HIV-related diarrhea. [AmFAR Tx Dir 1997;8(3)]
-
Enhancement of immune function in HIV infection / enhancement of
drug interactions. [Antimicro Agents Chemother 1992 Oct;36(10);
AmFAR Tx Dir 1995;7(4)]
-
HIV infection. [AmFAR Tx Dir 1995;7(4); Am J Hosp Pharm 1994 Feb
15;51(4)]
-
Under investigation in combination therapy for Mycobacterium avium
complex (MAC). [AmFAR Tx Dir December, 1997]
-
Approved as an anti-mycobacterial antibotic used in combination
regimens for tuberculosis. Under investigation in combination
therapy for Mycobacterium avium complex (MAC). Should be used in
conjunction with at least one other antituberculous drug. Drugs used
with ethambutol have included isoniazid, streptomycin, cycloserine,
ethionamide, pyrazinamide, viomycin, and aminosalicylic acid. [AmFAR
Tx Dir 1997;8(3); NIAID ACTG 135; AHFS Drug Information 1995]
-
Approved as an oral antibiotic used for treatment of several
common bacterial infections; under investigation for combination
therapy of Mycobacterium avium infection. [AmFAR Tx Dir 1997;8(3)]
-
Approved as an anti-mycobacterial drug for the treatment of
tuberculosis. Under investigation in combination regimens as
treatment for Mycobacterium avium infection and prophylaxis for
tuberculosis. Frequently used regimens are rifampin and isoniazid;
rifampin, isoniazid, and pyrazinamide; rifampin, isoniazid, and
ethambutol; and rifampin and ethambutol. [AmFAR Tx Dir 1995;7(4);
PDR 1997]
-
Primary HIV infection; Kaposi's sarcoma. [NCI 90 C-69; The Extra
Pharmacopoeia 1993]
-
Primary HIV infection. [AmFAR Tx Dir 1997;8(3)]
-
Primary HIV-infection - as a vaccine adjuvant for enhancement of
the immune response. [AmFAR Tx Dir 1993;6(4)]
-
Primary HIV infection. [AmFAR Tx Dir 1993;6(3)]
-
FDA approved, 6/12/96, for the prevention of disseminated
Mycobacterium avium complex (MAC) disease in persons with advanced
HIV infection. [U S Prescribing Information Pfizer Inc]
-
Primary HIV infection / prevention. [AmFAR Tx Dir December, 1997]
-
Under investigation for the treatment of Kaposi's sarcoma and
lymphoma. [AmFAR Tx Dir 1997;8(3)]
-
Primary HIV infection. [Med Res Rev 1993 May;13(3)]
-
Primary HIV infection. [Pharmacology 1993;46(2)]
-
FDA approved 12/23/93 (Biaxin) as a treatment for disseminated
mycobacterium avium complex ( MAC ). FDA approved 10/12/95 for the
prevention of disseminated Mycobacterium avium Complex ( MAC ) in
patients with advanced HIV infection. Under investigation in
combination therapy for toxoplasmosis. [Abbott Laboratories Drug
Information Packet, Oct 1985; AmFAR Tx Dir 1997;8(3); AHFS Drug
Information 1997]
-
Cytomegalovirus infections. [AmFAR Tx Dir 1993;6(3)]
-
HIV infection. [Int Conf AIDS 1992 Jul 19-24;8(2)]
-
Disseminated fungal infections including cryptococcal meningitis,
systemic candidiasis, coccidioidomycosis, and aspergillosis. FDA
approved 11/20/95 for patients with aspergillosis who are refractory
to or intolerant of conventional amphotericin B. [AmFAR Tx Dir
1995;7(4); FDA Bulletin]
-
Primary HIV infection. [Int Conf AIDS 1996 Jul 7-12;11(1)]
-
Cytomegalovirus infection. [AmFAR Tx Dir 1993;6(3)]
-
Investigated to determine the effects on the immune system, HIV
virus and antibody titers. [J Exp Med 1993 Feb 1;177(2); NIAID ACTG
141]
-
Under investigation for the treatment of cryptosporidiosis (cryptosporidium-associated
diarrhea). [AmFAR Tx Dir 1995;7(4); FDA 068A]
-
Oral candidiasis, gingivitis, prevention of thrush. [AmFAR Tx Dir
1995;7(4); AmFAR Tx Dir 1997;8(3)]
-
Condylomata acuminata (genital warts), Kaposi's sarcoma. [USP DI
1995]
-
Comparative study of HIVAC-1e and the smallpox vaccine in
previously vaccinated and unvaccinated volunteers. Control in
vaccine studies. [FDA 063A]
-
AIDS-Related Complex. [Dermatol Nurs 1993 Feb;5(1)]
-
Enhancement of immune function in HIV infection. Under
investigation for prevention of maternal-fetal HIV transmission.
Treatment of pediatric HIV infection. [FDA 060A; NIAID ACTG 185; USP
DI 1996]
-
Used to correct or minimize HIV associated neutropenia and/or
drug-induced neutropenia. In AIDS patients receiving zidovudine (ZDV)
therapy, filgrastim, either alone or with epoetin alfa, has been
used to decrease hematologic toxicity of ZDV. Similarly, filgrastim
has been evaluated in hematologic toxicity of ganciclovir, co-trimoxazole,
sulfadoxine, and pyrimethamine. FDA approved 2/21/91 for neutropenia
due to chemotherapy for cancers including lymphomas and Kaposi's
sarcoma. [HHS Press Release, June 27, 1994; AHFS Drug Information
1995]
-
FDA approved 9/23/92 for prevention of Mycobacterium avium Complex
(MAC) bacteremia and disseminated infections in patients with
advanced HIV infection. Designated by the FDA as an orphan drug for
this use. [AHFS Drug Information 1995]
-
FDA approved 11/25/92 for the treatment of mild to moderate PCP in
patients intolerant to standard therapies. Treatment and suppression
of T. gondii encephalitis. Primary prophylaxis of HIV-infected
persons at high risk for developing this disease. Limited studies
suggest that atovaquone may also be effective in the treatment of
ocular and cerebral toxoplasmosis in AIDS patients. [FDA Talk Paper;
USP DI 1995; Drug Evaluations Annual 1994]
-
Nutritional support. [FDA 041A; FDA 041B; AHFS Drug Information
1997]
-
Nutritional support. [FDA 041A; FDA 041B]
-
Kaposi's sarcoma. [AHFS Drug Information 1995]
-
Local treatment for cutaneous Kaposi's angiosarcoma; stimulation
of immune system. [Int Conf AIDS 1992 Jul 19-24;8(3); Int Conf AIDS
1992 Jul 19-24;8(2)]
-
Successfully used to treat isospora and cryptosporidium infection
in HIV patients. [Int Conf AIDS 1991 Jun 16-21;7(2)]
-
Cryptococcal meningitis, oropharyngeal candidiasis. [Antimicrob
Agents Chemother 1992 Dec;36(12); NIAID ACTG 125]
-
Treatment of cytomegalovirus infections. Phase I studies of
fiacitabine have been discontinued due to gastrointestinal toxicity
and severe fatigue. [AmFAR Tx Dir 1993;6(3); NIAID ACTG 122]
-
Being developed as an immunoprophylactic agent to reduce the
probability of infection following HIV-1 exposure, in settings such
as occupational or perinatal exposure to the virus. [AIDS Res Hum
Retroviruses]
-
Bacterial infections. [FDA 019A]
-
Treatment of bacterial infections. [FDA 019A]
-
Approved oral or topical antifungal drug used for the treatment of
systemic or topical fungal infections including candidiasis,
candiduria, blastomycosis, coccidioidomycosis, and histoplasmosis. [AmFAR
Tx Dir 1997;8(3)]
-
Treatment and prophylaxis of oropharyngeal candidiasis and
treatment of vulvovaginal candidiasis. [USP DI 1997]
-
An antibiotic under investigation as an alternative to penicillin
for the treatment of neurosyphilis. Single dose chancroid therapy
may be less effective in HIV patients and other anti-infectives
should be used. [AmFAR Tx Dir 1995;7(4); AHFS Drug Information 1997]
-
Used as control agent in immune response studies of AIDS patients.
[NIAID 87 I-114]
-
Inflammation and pain. [Int Conf AIDS 1992 Jul 19-24;8(3)]
-
Primary HIV infection. [Int Conf AIDS 1989 Jun 4-9;5]
-
Clofazamine has been used in combination with other
antimycobacterial drugs in immunocompromised patients with
Mycobacterium avium complex infections. Results have been
ineffective, bacteriologic cures are unusual and prognosis is poor.
[AHFS Drug Information 1997]
-
Enhancement of immune function in HIV infection in patients with
ARC or AIDS. Latest findings show no beneficial immunomodulatory
effects when patients are treated with ditiocarb sodium. [AmFAR Tx
Dir 1993;6(3)]
-
Stimulation of immune function in HIV patients. [AmFAR Tx Dir
1997;8(3)]
-
Treatment of HIV-related candidiasis. [AmFAR Tx Dir 1997;8(3)]
-
FDA approved 9/10/93 for treatment of anorexia, cachexia, and
unexplained substantial weight loss in patients with AIDS.
Designated an orphan drug by the FDA for this use. [AHFS Drug
Information 1997]
-
Approved for the treatment of anemia in both AZT-treated
HIV-infected subjects and chronic renal-failure patients. It is only
indicated in patients with endogenous erythropoietin levels less
than 500 mU/ml. [AmFAR Tx Dir 1996;8(2)]
-
Treatment of chronic diarrhea due to cryptosporidium in patients
with HIV infection. Per 4/2/93 communication - spiramycin is not
helpful or available for treatment of HIV cryptosporidiosis. [MMWR
March 9, 1984; Rhone-Poulenc Rorer Pharmaceuticals]
-
Treatment of depression. [PDR 1997]
-
Prevention of AIDS. [J Clin Immunol 1992 Nov;12(6)]
-
IV or topical antiviral drug active against herpes simplex and
varicella-zoster (VZV) viruses. Used to treat HSV (herpes simplex
virus) encephalitis; neonatal encephalitis, infections of the skin,
eyes, mouth, disseminated HSV and VZV infections with visceral
involvement, and herpes zoster (shingles) due to reactivated VZV
infections in immunosuppressed patients. [AmFAR Tx Dir 1997;8(3)]
-
AIDS-related depression. [NIAID ACTG 124]
-
Especially useful in preventing hyperuricemia and uric acid
nephropathy resulting from tissue breakdown after cancer
chemotherapy or radiation therapy. [AHFS Drug Information 1997]
-
Primary HIV infection: Persistent generalized lymphadenopathy and
ARC. [NIAID NS 403]
-
Kaposi's sarcoma; primary HIV infection; cytomegalovirus (CMV)
retinitis. Received licensure July 23, 1993. [Int Conf AIDS 1992 Jul
19-24;8(2); Ann Int Med 1990 Apr 15;112; Betaferon Patient Info Line
Last Updated July 30, 1993]
-
Possible use in reducing the glucuronidation of zidovudine (azidothymidine
(AZT)), thereby reducing the amount of AZT needed. [USP DI 1996]
-
Possible use in reducing the amount of AZT needed for treating
patients with symptomatic HIV infection (AIDS or symptomatic
AIDS-related complex (ARC)), via impairment of renal AZT
elimination. The combination of quinine sulfate and clindamycin may
be useful in the treatment of cryptosporidiosis. [Second
International Conference on AIDS 1986 Paris; AHFS Drug Information
1997]
-
Primary HIV infection. [NIAID 89 CC-62]
-
Used in conjunction with TMP/SMX (trimethoprim-sulfamethoxazole)
or alternative regimens at the beginning of treatment of an acute
episode of moderate to servere Pneumocystis carinii pneumonia. [AmFAR
Tx Dir 1997;8(3)]
-
Used with amphotericin B for treating acute cryptococcal
meningitis. [AmFAR Tx Dir 1996;8(2)]
-
Approved for anti-cancer therapy, under investigation for
lymphoma. [AmFAR Tx Dir 1997;8(3)]
-
Treatment of Kaposi's sarcoma. [AmFAR Tx Dir 1997;8(3)]
-
Under investigation for the treatment of Kaposi's sarcoma and
lymphoma. [AmFAR Tx Dir 1997;8(3)]
-
Used alone or in combination chemotherapy for the palliative
treatment of AIDS-related Kaposi's sarcoma. [AHFS Drug Information
1997]
-
Treatment of fungal infections: blastomycosis, pulmonary and
extrapulmonary; histoplasmosis, including chronic cavitary pulmonary
disease and disseminated, non-meningeal histoplasmosis;
aspergillosis, pulmonary and extrapulmonary, in patients who are
intolerant of or refractory to amphotericin B therapy; onychomycosis
due to dermatophytes of the toenail. [PDR 1997]
-
Stavudine was approved by the FDA on 6/27/94 for the treatment of
adults with HIV infection. The drug is now also approved for use in
children. Stavudine is most effective when used in combination with
other antiretroviral drugs such as ddI, 3TC and protease inhibitors.
[AmFAR Tx Dir 1998;9(2); HHS Press Release, June 27, 1994]
-
Primary HIV infection. Trials in AIDS/ARC patients indicated that
the drug had no significant effect on p24 antigen levels or CD4 cell
counts. [AmFAR Tx Dir 1995;7(4)]
-
Primary HIV infection. [AmFAR Tx Dir 1997;8(3)]
-
Primary HIV infection; studied as a treatment for HIV associated
neuropathy and neuropsychiatric impairment. [AmFAR Tx Dir 1995;7(4)]
-
Primary HIV infection. [USP DI 1995]
-
Used primarily in combination with other drugs for the treatment
of acute myelocytic leukemia. Under investigation for treatment of
Progressive Multifocal Leukoencephalopathy (PML). [AmFAR Tx Dir
1997;8(3)]
-
Pneumocystis carinii pneumonia (PCP). [USP DI 1995]
-
Dapsone has been used in conjunction with trimethoprim for the
treatment of initial episodes of Pneumocystis carinii pneumonia;
prophylactic therapy for the primary and secondary prevention of
Pneumocystis carinii pneumonia. [AHFS Drug Information 1997]
-
Kaposi's sarcoma. FDA approved 11/21/88 for adult Kaposi's
sarcoma. FDA approved 2/25/91 for chronic Non-A, Non-B hepatitis. [PDR
1997]
-
Treatment of AIDS-related Kaposi's sarcoma. FDA approved 11/21/88
for Kaposi's sarcoma. [PDR 1997]
-
The combination of pyrimethamine and sulfadoxine Fansidar is used
in the prophylaxis of Pneumocystis carinii pneumonia (PCP) and
toxoplasmosis and in patients who cannot tolerate co-trimoxazole
prophylaxis. [AHFS Drug Information 1997]
-
Primary HIV infection; limited effectiveness against Kaposi's
sarcoma. [J Acquir Immune Defic Syndr. 1989;2(3)]
-
Used in formulation with trimethoprim for treatment and
prophylaxis of Pneumocystis carinii pneumonia in AIDS patients. FDA
approved Bactrim and Septra 6/23/81 for PCP treatment and approved
1/7/94 for PCP prophylaxis. [AHFS Drug Information 1995]
-
Used in combination with sulfamethoxazole or dapsone for treatment
of Pneumocystis carinii pneumonia. FDA approved Bactrim and Septra
6/23/81 for PCP treatment and approved 1/7/94 for PCP prophylaxis. [AHFS
Drug Information 1995]
-
Primary HIV infection. [J Acquir Immune Defic Syndr 1995; 9(2)]
-
Primary HIV infection. [AHFS Drug Information 1995]
-
Used in combination with dapsone as primary and secondary
prophylaxis in treating Pneumocystis carinii pneumonia (PCP).
Combined with a sulfonamide for toxoplasmosis treatment. FDA
approved for toxoplasmosis. [AHFS Drug Information 1997]
-
When used with clindamycin, it is effective for acute Pneumocystis
carinii pneumonia (PCP). [USP DI 1995]
-
Pneumocystis carinii pneumonia (PCP). FDA approved 10/16/84 for
PCP treatment (im and iv). FDA approved 6/15/89 for PCP prophylaxis
(aerosol). [PDR 1995; FDA Office of AIDS and Special Health Issues]
-
Use in mixed drug therapy of patients with AIDS-associated
lymphoma. [NIAID ACTG 074]
-
Maintenance therapy of AIDS patients who were former drug abusers.
[NIAID ACTG 055]
-
Primary HIV infection - used for maintenance treatment of patients
unable to produce sufficient IgG antibodies and patients with
thrombocytopenia. Can prevent or modify certain infections in adult
and pediatric patients. FDA Approved 12/27/93 in HIV-infected
children as prophylactic therapy against certain bacterial
infections. [USP DI 1995]
-
Enhancement of immune response in HIV infection. [NIAID ACTG 024]
-
Under investigation for treatment of Mycobacterium tuberculosis
infection in HIV-positive people. [AmFAR Tx Dir 1996;8(2)]
-
Kaposi's sarcoma in selected patients, 18 years of age or older. [USP
DI 1996]
-
Indicated in the treatment of CMV (cytomegalovirus) retinitis in
immunocompromised individuals. FDA approved 6/26/89 for CMV
retinitis. FDA approved oral ganciclovir for marketing 1/5/95. [PDR
1997]
-
FDA approved 9/27/91 for cytomegalovirus retinitis in AIDS
patients. [AHFS Drug Information 1995; FDA Press Release]
-
Didanosine was the second antiretroviral agent approved by FDA for
HIV infection (1991), originally for the treatment of adults with
advanced HIV infection who have received prolonged prior treatment
with AZT. FDA recently approved didanosine as a first line therapy
against HIV when antiretroviral therapy is warranted. Current
recommendations generally advise using agents such as didanosine as
part of a potent three-drug combination. [AmFAR Tx Dir 1998;9(2)]
-
Zalcitabine was originally approved in combination with AZT in
patients with no prior antiretroviral experience. FDA approved
zalcitabine as monotherapy for HIV+ people who have experienced
disease progression while receiving AZT, or who are intolerant to
AZT. Zalcitabine monotherapy is not as effective as AZT/zalcitabine
comination therapy in prolonging the life of treatment-naive
patients. Current recommendations generally advise a three-drug
combination including a protease inhibitor. [AmFAR Tx Dir 1998;9(2)]
-
Treatment of HIV in AIDS patients. [NIAID ACTG 060; Int Conf AIDS
1989 Jun 4-9;5; USP DI 1996]
-
Acquired autoimmune hemolytic anemia. [PDR 1997]
-
Used to correct or minimize HIV-associated neutropenia and/or
drug-induced neutropenia(i.e., due to treatment with zidovudine,
interferon alfa, or cytotoxic chemotherapy). Used to increase
neutrophil counts in patients with CMV infection who develop
neutropenia while on ganciclovir, and in patients with nonmalignant
conditions who develop neutropenia while on myelosuppressive drugs.
FDA approved 3/5/91 for cancer patients with lymphomas or leukemia
who are receiving bone marrow transplants. [AHFS Drug Information
1996; HHS Press Release, June 27, 1994; Int Conf AIDS 1990 Jun
20-23;6(3)]
-
Treatment of mild-moderate Pneumocystis carinii pneumonia (PCP)
and toxoplasmosis in AIDS patients. [AHFS Drug Information 1996]
-
Treatment of patients with low CD4 cells and HIV infection. [NIAID
ACTG 046]
-
Persistent generalized lymphadenopathy (PGL) and symptomatic HIV
infection. [NIAID ACTG 022]
-
Initial treatment and management of recurrent Herpes virus (genitalis;
simplex; zoster) infections and chickenpox infections in
immunocompromised patients. [PDR 1997; USP DI 1996]
-
Treatment of mild to moderate fever and pain. [AHFS Drug
Information 1996]
-
Acute cryptococcal meningitis. [AHFS Drug Information 1996]
-
FDA approved 1/29/90 for the treatment of cryptococcal meningitis
and oropharyngeal and esophageal candidiasis. [PDR 1995]
-
Zidovudine is approved for the treatment of all HIV positive
people with a CD4 count less than 500. Results of numerous clinical
trials indicate that zidovudine is most effective when used in
combination with other antiretroviral drugs. At its peak
effectiveness in treatment-naive patients, zidovudine reduces HIV
RNA levels by roughly 70%, and as a monotherapy cannot control viral
replication in the majority of HIV infected patients. [AmFAR Tx Dir
1998;9(2)]
-
Primary HIV infection. [Int Conf AIDS 1993 Jun 6-11;9(1)]
-
Prevention of mucositis and bone marrow toxicity associated with
Trimetrexate when the latter is used for treatment of Pneumocystis
carinii pneumonia (PCP) in AIDS patients. [NIAID ACTG 039]
-
Primary HIV infection (stimulation of immune system). [NIAID ACTG
054]
-
|
|
